Drug Profile


Alternative Names: MM-D37K chimeric peptide; MMD37K

Latest Information Update: 13 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MetaMax
  • Class Cytostatics; Peptides
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Bladder cancer; Gastrointestinal cancer; Glioblastoma; Malignant melanoma

Most Recent Events

  • 13 Jun 2018 MM D37K is still in phase I/II trials for Bladder cancer, Gastrointestinal cancer (pancreatic, gastric, oesophageal, liver and colorectal cancers), Glioblastoma and Malignant melanoma in Russia (IV) (Metamas website, June 2018)
  • 31 May 2013 Pharmacodynamics & pharmacokinetics data from preclinical studies in Solid tumours presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO-2013)
  • 23 Nov 2012 Preclinical trials in Solid tumours in Russia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top